Beautiful Virgin Islands

Monday, Oct 06, 2025

‘Durable Demand’: Pfizer CEO Expects $26B COVID-19 Vaccine Profits in 2021, Plans for Boosters

‘Durable Demand’: Pfizer CEO Expects $26B COVID-19 Vaccine Profits in 2021, Plans for Boosters

Pharmaceutical giant Pfizer is banking on COVID-19 being a major profit-driver for years to come as the company lines up vaccine delivery contracts for as far away as 2024. Corporate leaders have previously spoken of plans to dramatically increase the price of a jab once governments stop being the primary buyer.

In a first quarter earnings statement on Tuesday, Pfizer Chairman and CEO Albert Bourla said the company expects to make $26 billion in revenue from sales this year of the COVID-19 vaccine it jointly produced with German firm BioNTech. However, he expects that vaccine manufacturing will only increase in future years, with the company preparing to make 3 billion doses in 2022.

While some of those will be two-dose treatments for first-time recipients, the company also expects COVID-19 to become endemic and is increasingly expecting to deliver annual booster shots as well, which could potentially be tweaked to protect from whichever strain is expected to be dominant that year.

“Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome,” Bourla said. “It is our hope that the Pfizer-BioNTech vaccine will continue to have a global impact by helping to get the devastating pandemic under control and helping economies around the world not only open – but stay open – creating a scenario in which Pfizer can continue to be both a leader and a beneficiary.”

Multi-Year Contracts Unveiled


Bourla spelled out that Pfizer has already reached an agreement with Canada to deliver as many as 125 million doses in 2022 and 2023, with the option of another 60 million doses in 2024.

Canada’s population is just 37.6 million. According to government statistics, Ottawa has already spent more than $1 billion procuring as many as 180 million vaccines, including up to 76 million from Pfizer expected to begin shipping sometime this week, but also three others from Moderna, Johnson & Johnson, and AstraZeneca, the lattermost of which includes 2 million doses donated by the United States.

Bourla also said Pfizer has signed a deal to supply the United Kingdom with up to 60 million more doses in 2021 and to supply Israel with enough doses in 2022 “for the government to boost every eligible citizen, subject to local guidelines – with the option to purchase millions of additional doses for additional boosters.” It’s unclear if this is intended to include the millions of Palestinians who live under Israeli occupation but are not considered Israeli citizens and have not been given the same access to COVID-19 vaccines by Jerusalem.

The Times of Israel reported on Wednesday that Israel already has more than enough vaccines for its population and is expecting millions more doses to arrive, which it may give away to other nations but has also hinted may simply be thrown away. Meanwhile, less than 1% of Palestinians have been fully vaccinated, most of whom are workers who come into daily contact with Israelis because, as the paper put it, “Israel does not believe it is legally required to vaccinate the Palestinians.”

Bourla also noted that younger age cohorts were also being tested for vaccination: ages 2 to 5, 5 to 11, and 12 to 16, with another test on six-month-olds to two-year-olds expected later this year. Data from the other tests is expected before the end of the summer.

Not all of the benefits for Pfizer will come from the vaccine itself, though: the research behind the new mRNA vaccine design has yielded gains on new fronts, including flu shots and antiviral treatments, and could potentially be applied to treating other rare diseases like the autoimmune disease alopecia areata. Pfizer is also looking at creating an antiviral treatment for COVID-19 to be administered as either a shot or a pill to people who have contracted the disease, similarly to influenza antivirals.

Unequal Access for Third World


Pfizer CFO Frank D’Amelio also said in the Tuesday meeting that as a percentage of total company revenue, the COVID-19 vaccine has increased to 36% from the 25% projection made at the start of the year. He noted Pfizer expects to make 2.5 billion doses in 2021 and has contracted to deliver 1.6 billion doses this year.

At present, Pfizer’s money from COVID-19 vaccines is derived purely from government contracts. The company offers three tiers of prices depending on the relative wealth of the buying country, D’Amelio said on the Tuesday call. It’s unclear how disparate those prices are, but a high-wealth country paid $19.50 per shot while Malaysia, ranked 36th in the world by gross domestic product, paid the equivalent of $18.79 per shot.

Other nations have not been so lucky. One unnamed Latin American nation, which could not be identified due to a confidentiality agreement signed with Pfizer, had to agree to bear the costs of lawsuits against Pfizer for adverse effects of the COVID-19 vaccines, according to the Bureau of Investigative Journalism. Negotiations with Brazil and Argentina fell apart, according to the report, after Pfizer demanded they put up sovereign wealth assets like embassies and military bases as collateral against future legal cases.

An official from the unnamed country told TBIJ the negotiations with Pfizer felt like “high-level bullying” and that it felt like the health of their citizens were being “held to ransom.”

Coming Price Hike Amid Anti-TRIPS Push


In a February call with Wall Street investors, D’Amelio indicated that the company’s pricing will change significantly once governments stop being their primary customer and the company can excusably increase prices to match their other vaccines. While Pfizer is presently getting $19.50 per dose in the US, he noted that “that’s not a normal price, like we typically get for a vaccine - $150, $175 per dose ... Let's go beyond a pandemic pricing environment, the environment we're currently in: Obviously, we're going to get more on price.”

That amounts to a nearly 900% increase over present prices. It’s no coincidence either, then, that Pfizer has very strongly opposed the movement by more than 80 Global South nations, led by India and South Africa, to convince the World Trade Organization to waive intellectual property laws with regard to COVID-19 vaccines. The Trade-Related Aspects of Intellectual Property (TRIPS) agreement put in place in 1995 globalized IP laws, making the manufacture of cheap generic versions of drugs all but impossible.

TRIPS came just as the first anti-HIV/AIDS drugs entered the market and as the virus spread across Africa, leaving the world’s poorest nations totally unable to afford life-saving drugs that were priced so high that even First World customers found them prohibitively expensive. AIDS deaths didn’t peak for another decade, reaching in 2004 more than twice the number of deaths as in 1995, with an estimated 1.7 million people dying of AIDS complications that year.

On Wednesday afternoon, US Trade Representative Katherine Tai announced that the Biden administration was coming out in support of patent waivers for COVID-19 vaccines, saying they were presently in negotiation with the WTO over the matter.

“This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures,” Tai said in a press release.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Munich Airport Reopens After Second Drone Shutdown
France Names New Government Amid Political Crisis
Trump Stands Firm in Shutdown Showdown and Declares War on Drug Cartels — Turning Crisis into Opportunity
Surge of U.S. Billionaires Transforms London’s Peninsula Apartments into Ultra-Luxury Stronghold
Pro Europe and Anti-War Babiš Poised to Return to Power After Czech Parliamentary Vote
Jeff Bezos Calls AI Surge a ‘Good’ Bubble, Urges Focus on Lasting Innovation
Japan’s Ruling Party Chooses Sanae Takaichi, Clearing Path to First Female Prime Minister
Sean ‘Diddy’ Combs Sentenced to Fifty Months in Prison Following Prostitution Conviction
Taylor Swift’s ‘Showgirl’ Launch Extends Billion-Dollar Empire
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
×